Page 29 - Small Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ICON plc: ICON wins multiple categories in 2021 CRO Leadership Awards for the fourth year in a row Quality (Overall, Big Pharma) Life Science Leader magazine and Clinical Leader once again teamed up with Industry Standard Research (ISR) to determine the award recipients. They assessed sixty contract research organisations on over 20 performance metrics in ISR's annual CRO Quality Benchmarking survey. Survey participants were recruited from pharma and biopharma companies of all sizes and were screened for decision-making influence related to working with contract research organisations. Dr Ste...

Press release content from Business Wire. The AP news staff was not involved in its creation. ICON wins multiple categories in 2021 CRO Leadership Awards for the fourth year in a row April 20, 2021 GMT DUBLIN--(BUSINESS WIRE)--Apr 20, 2021-- ICON plc, (NASDAQ: ICLR) ICON plc, a global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, has won multiple categories in the annual CRO Leadership Awards. This is the fifth year ICON has enjoyed success in the CRO Leadership Awards, having won multiple categories previously ...

BBC News By Rachel Schraer image copyrightGetty Images A powerful hallucinogenic drug known for its part in shamanic rituals is being trialled as a potential cure for depression for the first time. Participants will be given the drug DMT, followed by talking therapy. It is hoped this could offer an alternative for the significant number of people who don't respond to conventional pills for depression. Psychedelic-assisted therapy might offer longer-term relief from symptoms, some researchers believe. A growing body of evidence indicates other psychedelic drugs, particularly alongside talkin...

A powerful hallucinogenic drug that has been used in shamanic rituals is being trialled by a British firm as a potential cure for depression.  Small Pharma will give volunteers suffering from depression DMT, a hallucinogenic tryptamine with similar psychedelic effects to LSD and magic mushrooms. The developers hope the drug will help a 'significant number' of people who don't currently respond to conventional treatments or medication for depression. One of the active ingredients of DMT is 'ayahuasca' which is a traditional Amazonian plant medicine used ritually by some tribes to bring 'spiri...

The psychoactive drug DMT, or N, N-dimethyltryptamine, produces effects similar to those of psychedelics, like LSD and magic mushrooms, with its capability to cure...